Revenue grew 49% year-over-year to SEK 23.9 million, with a 66% gross margin and positive Q4 EBITDA. The acquisition of Pharmacure and strong consumer segment growth drove expansion, while new scientific validation supports future drug delivery opportunities.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.